Evidence map›Paper›PMID 42001072›Full record

Observational studyBMC urology2026

Impact of comorbidity on patient reported outcome measures for men with localised prostate cancer.

Matthew G Parry, Anissa V Bailey, Thomas R Belin, David Elashoff, Claire Foster, Ian Graham, Christoph Kowalski, Lorna Kwan, Jeremy Millar, Nora Tabea Sibert and 5 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Matthew G ParryDivision of Surgical and Interventional Science, University College London, London, UK. matthew.parry@ucl.ac.uk.ORCID http://orcid.org/0000-0002-9695-6052
Anissa V BaileyDepartments of OBGYN, Surgery, & Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Thomas R BelinDepartment of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, USA.
David ElashoffDepartments of Biostatistics and Medicine, University of California, Los Angeles, CA, USA.
Claire FosterUniversity of Southampton, Southampton, UK.
Ian GrahamOttawa Hospital Research Institute, Ottawa, Canada.
Christoph KowalskiDepartment of Health Services Research, German Cancer Society, Berlin, Germany.
Lorna KwanDepartments of OBGYN, Surgery, & Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Jeremy MillarMonash University, Melbourne, Australia.
Nora Tabea SibertDepartment of Health Services Research, German Cancer Society, Berlin, Germany.
Sarah WellerMovember Institute of Men's Health, Melbourne, Australia.
Holly WilhalmeDepartment of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Mark S LitwinUniversity of California, Los Angeles, USA.
Caroline M MooreDivision of Surgical and Interventional Science, University College London, London, UK.
TrueNTH Global Registry

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrinary and sexual function are impacted by prostate cancer treatment but also by comorbidities. We aimed to report the impact of comorbidities on functional outcomes after prostate cancer treatment.

methodsWe used patient reported EPIC-26, at baseline and 12 months, from a multicenter, prospective international cohort. Forest plots were constructed for urinary and sexual function, according to treatment, age and comorbidities (heart disease, hypertension and diabetes mellitus).

resultsWe identified 10,928 patients diagnosed with non-metastatic prostate cancer with complete PROMs at baseline and at 12 months. Urinary and sexual function at baseline varied with age and comorbidities, but the biggest impact on 12-month function was the treatment itself. Surgery had a greater impact on urinary function compared to radiotherapy, irrespective of comorbidities, but this was only observed for sexual function in those with no comorbidities. Men of younger age and those with no comorbidities had the best preservation of urinary and sexual function after treatment, but a floor effect was observed whereby those with better baseline sexual function reported larger post-treatment differences.

conclusionsThe impact of age and comorbidity on functional outcomes after prostate cancer treatment is minimal when considered against the impact of the treatment itself.

Indexed as

Patient Reported Outcome MeasuresProstatic NeoplasmsAgedComorbidityHumansMaleMiddle AgedProspective StudiesComorbiditiesFunctional outcomesInternational RegistryPatient-reported Outcome MeasuresProstate cancer

Identifiers

PMID42001072
PMCPMC13231530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.